Key Takeaways Strong clinical progress and unique program design could accelerate commercialization, market share gains, and pricing power, positioning Silence for significant margin and revenue growth. Expanding pipeline, regained global rights, and preclinical advances in RNAi therapeutics create long-term advantage and substantial high-margin revenue opportunities beyond current market expectations.Read more
Key Takeaways The company's strategic partnerships and collaborations could reduce financial risk and enhance revenue growth through shared commercialization and milestone payments. Successful study results and orphan drug designation might lead to dominance in niche markets, improving future earnings and net margins.Read more
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
